Identification

Summary

Potassium acetate is a medication used to treat hypokalemia.

Brand Names
Hyperlyte, Normosol-M
Generic Name
Potassium acetate
DrugBank Accession Number
DB14498
Background

Not Available

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 98.1423
Monoisotopic: 97.977011201
Chemical Formula
C2H3KO2
Synonyms
  • Potassium acetate

Pharmacology

Indication

Potassium is used to regulate hypokalemia as a primary condition or secondary to other medical conditions.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Potassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium is maintained by ion pumps in the cell membrane. The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity.

TargetActionsOrganism
USodium/potassium-transporting ATPase subunit alpha-1Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Mostly urine but also skin and feces.

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
AcebutololPotassium acetate may increase the hyperkalemic activities of Acebutolol.
AceclofenacPotassium acetate may increase the hyperkalemic activities of Aceclofenac.
AcemetacinPotassium acetate may increase the hyperkalemic activities of Acemetacin.
AcetaminophenAcetaminophen may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Potassium acetate which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidPotassium acetate may increase the hyperkalemic activities of Acetylsalicylic acid.
AclidiniumAclidinium may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
AcrivastineAcrivastine may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Active Moieties
NameKindUNIICASInChI Key
Potassium cationionic295O53K15224203-36-9NPYPAHLBTDXSSS-UHFFFAOYSA-N
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Potassium AcetateInjection, solution, concentrate392 mg/1mLIntravenousAmerican Regent1990-09-302014-07-01US flag
Potassium AcetateLiquid392 mg / mLIntravenousSandoz Canada Incorporated1988-12-312016-10-24Canada flag
Potassium AcetateInjection, solution, concentrate3.93 g/20mLIntravenousHospira, Inc.2014-03-27Not applicableUS flag
Potassium AcetateInjection, solution196 mg/1mLIntravenousAmerican Regent1990-09-302012-11-29US flag
Potassium AcetateInjection, solution, concentrate196.3 mg/1mLIntravenousHospira, Inc.2013-12-23Not applicableUS flag
Potassium Acetate Inj 2meq/mlSolution2 mEq / mLIntravenousAbbott1984-12-312008-06-06Canada flag
Potassium Acetate Inj 392mg/ml USPLiquid392 mg / mLIntravenousLyphomed, Division Of Fujisawa Canada Inc.1984-12-311996-09-10Canada flag
Potassium Acetate InjectionSolution392 mg / mLIntravenousFresenius Kabi1984-12-31Not applicableCanada flag
Potassium Acetate Injection USPLiquid39.2 % w/vIntravenousOmega Laboratories Ltd2016-07-18Not applicableCanada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Potassium AcetateInjection, solution, concentrate3.93 g/20mLIntravenousExela Pharma Sciences, LLC2016-01-07Not applicableUS flag
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
DBL POTASSIUM ACETATE CONCENTRATED INJECTION 2.45 g/5 mlInjection2.45 g/5mlIntravenousHOSPIRA SINGAPORE PTE. LTD.1991-05-21Not applicable
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Aminoplasmal B. Braun 10%E Solution for Intravenous InfusionPotassium acetate (2.453 g/1000ml) + Alanine (10.5 g/1000ml) + Arginine (11.5 g/1000ml) + Aspartic acid (5.6 g/1000ml) + Glutamic acid (7.2 g/1000ml) + Glycine (12 g/1000ml) + Histidine (3 g/1000ml) + Isoleucine (5 g/1000ml) + Leucine (8.9 g/1000ml) + Lysine hydrochloride (8.56 g/1000ml) + Magnesium chloride hexahydrate (0.508 g/1000ml) + Methionine (4.4 g/1000ml) + Phenylalanine (4.7 g/1000ml) + Proline (5.5 g/1000ml) + Serine (2.3 g/1000ml) + Sodium acetate trihydrate (2.858 g/1000ml) + Sodium hydroxide (0.36 g/1000ml) + Sodium phosphate, dibasic dodecahydrate (3.581 g/1000ml) + Threonine (4.2 g/1000ml) + Tryptophan (1.6 g/1000ml) + Tyrosine (0.4 g/1000ml) + Valine (6.2 g/1000ml)Injection, solutionIntravenousB.BRAUN MEDICAL INDUSTRIES SDN BHD2020-09-08Not applicableMalaysia flag
AMINOPLASMAL B.BRAUN 10% E SOLUTION FOR INFUSIONPotassium acetate (2.453 g/1000ml) + Alanine (10.50 g/1000ml) + Arginine (11.50 g/1000ml) + Aspartic acid (5.60 g/1000ml) + Glutamic acid (7.20 g/1000ml) + Glycine (12.00 g/1000ml) + Histidine (3.00 g/1000ml) + Isoleucine (5.00 g/1000ml) + Leucine (8.90 g/1000ml) + Lysine hydrochloride (8.56 g/1000ml) + Magnesium chloride hexahydrate (0.508 g/1000ml) + Methionine (4.40 g/1000ml) + Phenylalanine (4.70 g/1000ml) + Proline (5.50 g/1000ml) + Serine (2.30 g/1000ml) + Sodium acetate trihydrate (2.858 g/1000ml) + Sodium hydroxide (0.360 g/1000ml) + Sodium phosphate, dibasic dodecahydrate (3.581 g/1000ml) + Threonine (4.20 g/1000ml) + Tryptophan (1.60 g/1000ml) + Tyrosine (0.40 g/1000ml) + Valine (6.20 g/1000ml)SolutionIntravenousB. BRAUN SINGAPORE PTE LTD2018-01-23Not applicable
AMINOPLASMAL-10% E INFUSIONPotassium acetate (2.45 g/l) + Acetylcysteine (0.5 g/l) + Alanine (13.7 g/l) + Arginine (9.2 g/l) + Asparagine (3.27 g/l) + Aspartic acid (1.3 g/l) + Glutamic acid (4.6 g/l) + Glycine (7.9 g/l) + Histidine (5.2 g/l) + Isoleucine (5.1 g/l) + Leucine (8.9 g/l) + Lysine hydrochloride (5.6 g/l) + Magnesium acetate (0.56 g/l) + Malic acid (1.01 g/l) + Methionine (3.8 g/l) + N-acetyltyrosine (1 g/l) + Ornithine hydrochloride (2.51 g/l) + Phenylalanine (5.1 g/l) + Proline (8.9 g/l) + Serine (2.4 g/l) + Sodium acetate (3.95 g/l) + Sodium hydroxide (0.2 g/l) + Sodium phosphate, monobasic (1.4 g/l) + Threonine (4.1 g/l) + Tryptophan (1.8 g/l) + Tyrosine (0.3 g/l) + Valine (4.8 g/l)InjectionIntravenousB. BRAUN SINGAPORE PTE LTD1991-05-13Not applicable
AMINOPLASMAL-5% E INFUSIONPotassium acetate (2.45 g/1000ml) + Acetylcysteine (0.25 g/1000ml) + Alanine (6.85 g/1000ml) + Arginine (4.6 g/1000ml) + Asparagine (1.64 g/1000ml) + Aspartic acid (0.65 g/1000ml) + Glutamic acid (2.3 g/1000ml) + Glycine (3.95 g/1000ml) + Histidine (2.6 g/1000ml) + Isoleucine (2.55 g/1000ml) + Leucine (4.45 g/1000ml) + Lysine hydrochloride (2.8 g/1000ml) + Magnesium acetate (0.56 g/1000ml) + Malic acid (1.01 g/1000ml) + Methionine (1.9 g/1000ml) + N-acetyltyrosine (0.35 g/1000ml) + Ornithine hydrochloride (1.25 g/1000ml) + Phenylalanine (2.55 g/1000ml) + Proline (4.45 g/1000ml) + Serine (1.2 g/1000ml) + Sodium acetate (3.95 g/1000ml) + Sodium hydroxide (0.2 g/1000ml) + Sodium phosphate, monobasic (1.4 g/1000ml) + Threonine (2.05 g/1000ml) + Tryptophan (0.9 g/1000ml) + Tyrosine (0.3 g/1000ml) + Valine (2.4 g/1000ml)InjectionIntravenousB. BRAUN SINGAPORE PTE LTD1991-05-13Not applicable
AMINOPLASMAL® 10% EPotassium acetate (2.453 g) + Alanine (10.5 g) + Arginine (11.5 g) + Aspartic acid (5.6 g) + Glutamic acid (7.2 g) + Glycine (12 g) + Histidine (3 g) + Isoleucine (5 g) + Leucine (8.9 g) + Lysine hydrochloride (8.56 g) + Magnesium chloride hexahydrate (0.508 g) + Phenylalanine (4.7 g) + Proline (5.5 g) + Racemethionine (4.4 g) + Serine (2.3 g) + Sodium acetate trihydrate (2.858 g) + Sodium hydroxide (0.36 g) + Sodium phosphate, dibasic dodecahydrate (3.581 g) + Threonine (4.2 g) + Tryptophan (1.6 g) + Tyrosine (0.4 g) + Valine (6.2 g)SolutionIntravenousB. BRAUN MEDICAL S.A.2015-07-27Not applicableColombia flag
AminosynPotassium acetate (128 mg/100mL) + Alanine (448 mg/100mL) + Arginine (343 mg/100mL) + Glycine (448 mg/100mL) + Histidine (105 mg/100mL) + Isoleucine (252 mg/100mL) + Leucine (329 mg/100mL) + Lysine acetate (252 mg/100mL) + Magnesium acetate (21 mg/100mL) + Methionine (140 mg/100mL) + Phenylalanine (154 mg/100mL) + Phosphoric acid (40 mg/100mL) + Proline (300 mg/100mL) + Serine (147 mg/100mL) + Sodium chloride (234 mg/100mL) + Threonine (182 mg/100mL) + Tryptophan (56 mg/100mL) + Tyrosine (31 mg/100mL) + Valine (280 mg/100mL)Injection, solutionIntravenousHospira, Inc.2011-03-232017-11-01US flag
Aminosyn 3.5% MPotassium acetate (128 mg / 100 mL) + Alanine (448 mg / 100 mL) + Arginine (343 mg / 100 mL) + Glycine (448 mg / 100 mL) + Histidine (105 mg / 100 mL) + Isoleucine (252 mg / 100 mL) + Leucine (329 mg / 100 mL) + Lysine acetate (252 mg / 100 mL) + Magnesium acetate (21 mg / 100 mL) + Methionine (140 mg / 100 mL) + Phenylalanine (154 mg / 100 mL) + Proline (300 mg / 100 mL) + Serine (147 mg / 100 mL) + Sodium chloride (234 mg / 100 mL) + Threonine (182 mg / 100 mL) + Tryptophan (56 mg / 100 mL) + Tyrosine (31 mg / 100 mL) + Valine (280 mg / 100 mL)LiquidIntravenousAbbott1980-12-311999-08-09Canada flag
Hyperlyte (multi-electrolyte Concentrate)Potassium acetate (690 mg / 25 mL) + Calcium acetate (440 mg / 25 mL) + Sodium gluconate (1.09 g / 25 mL) + Magnesium acetate (860 mg / 25 mL) + Potassium chloride (2.46 g / 25 mL) + Sodium acetate (2.72 g / 25 mL)LiquidIntravenousB. Braun Medical Inc.1998-09-042017-07-15Canada flag
Hyperlyte CR Multi-electrolyte ConcentratePotassium acetate (1.96 g / 20 mL) + Calcium chloride (370 mg / 20 mL) + Magnesium chloride (510 mg / 20 mL) + Sodium acetate (680 mg / 20 mL) + Sodium chloride (1.17 g / 20 mL)LiquidIntravenousB. Braun Medical Inc.1998-09-03Not applicableCanada flag
LypholytePotassium acetate (690 mg / 20 mL) + Calcium acetate (440 mg / 20 mL) + Sodium gluconate (1.1 g / 20 mL) + Magnesium acetate (860 mg / 20 mL) + Potassium chloride (2.5 g / 20 mL) + Sodium acetate (2.7 g / 20 mL)SolutionIntravenousPartners Health Care, Inc.1996-08-142008-01-10Canada flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Hyperlyte CRPotassium acetate (1.96 g/20mL) + Calcium chloride dihydrate (0.37 g/20mL) + Magnesium chloride hexahydrate (0.51 g/20mL) + Sodium acetate trihydrate (0.68 g/20mL) + Sodium chloride (1.17 g/20mL)Injection, solution, concentrateIntravenousB. Braun Medical Inc.2012-04-12Not applicableUS flag
NutrilytePotassium acetate (34.5 mg/1mL) + Calcium acetate (22 mg/1mL) + Sodium gluconate (55 mg/1mL) + Magnesium acetate (43 mg/1mL) + Potassium chloride (125 mg/1mL) + Sodium acetate trihydrate (135 mg/1mL)Injection, solution, concentrateIntravenousAmerican Regent1990-09-302013-05-08US flag
Nutrilyte IIPotassium acetate (98 mg/1mL) + Calcium chloride dihydrate (16.55 mg/1mL) + Magnesium chloride hexahydrate (25.5 mg/1mL) + Sodium acetate trihydrate (64.6 mg/1mL) + Sodium chloride (74.5 mg/1mL)Injection, solution, concentrateIntravenousAmerican Regent1990-10-012014-01-01US flag
Nutrilyte IIPotassium acetate (98 mg/1mL) + Calcium chloride dihydrate (16.55 mg/1mL) + Magnesium chloride hexahydrate (25.5 mg/1mL) + Sodium acetate trihydrate (64.6 mg/1mL) + Sodium chloride (74.5 mg/1mL)Injection, solution, concentrateIntravenousAmerican Regent1990-10-012014-01-01US flag
Potassium AcetatePotassium acetate (392 mg/1mL)Injection, solution, concentrateIntravenousAmerican Regent1990-09-302014-07-01US flag
Potassium AcetatePotassium acetate (196 mg/1mL)Injection, solutionIntravenousAmerican Regent1990-09-302012-11-29US flag

Categories

ATC Codes
B05XA17 — Potassium acetate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as acetate salts. These are organic compounds containing acetic acid as its acid component.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Carboxylic acid derivatives
Direct Parent
Acetate salts
Alternative Parents
Monocarboxylic acids and derivatives / Carboxylic acids / Organic potassium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Acetate salt / Aliphatic acyclic compound / Carbonyl group / Carboxylic acid / Hydrocarbon derivative / Monocarboxylic acid or derivatives / Organic alkali metal salt / Organic oxide / Organic oxygen compound / Organic potassium salt
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
potassium salt (CHEBI:32029)
Affected organisms
Not Available

Chemical Identifiers

UNII
M911911U02
CAS number
127-08-2
InChI Key
SCVFZCLFOSHCOH-UHFFFAOYSA-M
InChI
InChI=1S/C2H4O2.K/c1-2(3)4;/h1H3,(H,3,4);/q;+1/p-1
IUPAC Name
potassium acetate
SMILES
[K+].CC([O-])=O

References

General References
Not Available
KEGG Compound
C12554
ChemSpider
29104
ChEBI
32029
ChEMBL
CHEMBL1201058
Wikipedia
Potassium_acetate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentCritically Ill Patients1
3CompletedTreatmentParenteral Nutrition for Patients With Proven Insufficient Enteral Resorption1
2CompletedTreatmentAcute Heart Failure (AHF) / Decompensated Heart Failure / Heart Failure1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionIntravenous10.50 g/1000ml
InjectionIntravenous0.5 g/l
InjectionIntravenous0.25 g/1000ml
SolutionIntravenous
InjectionIntravenous2.45 g/5ml
Injection, emulsionParenteral
Injection, emulsionIntravenous
EmulsionParenteral
EmulsionIntravenous
Injection, emulsionIntravenous4.656 g/1000ml
Injection, emulsionIntravenous6.792 g/1000ml
Injection, solution, concentrateIntravenous
InjectionIntravenous
LiquidIntravenous
Injection, solutionIntravenous
Injection, solutionParenteral
Injection, solution, concentrateIntravenous
Injection, solution, concentrateIntravenous3 MEQ/ML
Injection, solutionIntravenous196 mg/1mL
Injection, solution, concentrateIntravenous196.3 mg/1mL
Injection, solution, concentrateIntravenous3.93 g/20mL
Injection, solution, concentrateIntravenous392 mg/1mL
SolutionIntravenous2 mEq / mL
LiquidIntravenous392 mg / mL
SolutionIntravenous392 mg / mL
LiquidIntravenous39.2 % w/v
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility342.0 mg/mLALOGPS
logP-0.27ALOGPS
logP-0.22ChemAxon
logS0.54ALOGPS
pKa (Strongest Acidic)4.54ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area40.13 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity23.48 m3·mol-1ChemAxon
Polarizability4.96 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Silva E, Gomes P, Soares-da-Silva P: Overexpression of Na(+)/K (+)-ATPase parallels the increase in sodium transport and potassium recycling in an in vitro model of proximal tubule cellular ageing. J Membr Biol. 2006;212(3):163-75. Epub 2007 Feb 28. [Article]
  2. Li C, Geering K, Horisberger JD: The third sodium binding site of Na,K-ATPase is functionally linked to acidic pH-activated inward current. J Membr Biol. 2006;213(1):1-9. Epub 2007 Mar 8. [Article]
  3. Stanely Mainzen Prince P, Karthick M: Preventive effect of rutin on lipids, lipoproteins, and ATPases in normal and isoproterenol-induced myocardial infarction in rats. J Biochem Mol Toxicol. 2007;21(1):1-6. [Article]
  4. Simon WA, Herrmann M, Klein T, Shin JM, Huber R, Senn-Bilfinger J, Postius S: Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007 Jun;321(3):866-74. Epub 2007 Mar 16. [Article]
  5. Iannello S, Milazzo P, Belfiore F: Animal and human tissue Na,K-ATPase in normal and insulin-resistant states: regulation, behaviour and interpretative hypothesis on NEFA effects. Obes Rev. 2007 May;8(3):231-51. [Article]

Drug created at July 11, 2018 16:28 / Updated at October 26, 2021 21:40